Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Janux Therapeutics, Inc.

JANX · Nasdaq · CIK 0001817713 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

11 Form 4 transaction lines observed in the same window
2 sales · 9 option, withholding, award, gift or other lines

Last qualifying purchase2025-03-07 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. · $3.4M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Campbell David AlanPresident and CEO
○○
Simson JakeDirector
○
Kung WinstonDirector
○
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Director; Director,TenPercentOwner
○
Hernday NatashaDirector
○
DOBMEIER ERICDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-03-07 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M..

Recent Form 4 activity

0Purchases
12Sales
20Other Form 4 lines
22SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER9 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
5,684,346
Previous report
5,891,965
Avg daily volume
969,533
Days to cover
5.9

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-03-07Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Purchase (P)Common Stock110,206USD 31.02USD 3,418,590SEC filing ↗
2025-03-06Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Purchase (P)Common Stock372,093USD 30.78USD 11,453,023SEC filing ↗
2025-03-05Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Purchase (P)Common Stock341,742USD 30.64USD 10,471,352SEC filing ↗
2024-10-18Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Purchase (P)Common Stock1,200,000USD 44.75USD 53,700,000SEC filing ↗
2023-11-13Reardon TighePurchase (P)Common Stock849,854USD 5.87USD 4,988,643SEC filing ↗
2023-11-13Lichter JayPurchase (P)Common Stock849,854USD 5.87USD 4,988,643SEC filing ↗
2023-11-13Avalon BioVentures I, LP; Avalon BioVentures SPV I, L.P.; Avalon Ventures XI, L.P.Purchase (P)Common Stock849,854USD 5.87USD 4,988,643SEC filing ↗
2023-07-19Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Purchase (P)Common Stock495,008USD 12.46USD 6,167,800SEC filing ↗
2021-06-15Thompson Peter A.Purchase (P)Common Stock705,853USD 17.00USD 11,999,501SEC filing ↗
2021-06-15Reardon TighePurchase (P)Common Stock629,411USD 17.00USD 10,699,987SEC filing ↗
2021-06-15ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock705,853USD 17.00USD 11,999,501SEC filing ↗
2021-06-15Lichter JayPurchase (P)Common Stock629,411USD 17.00USD 10,699,987SEC filing ↗
2021-06-15Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock2,941,176USD 17.00USD 49,999,992SEC filing ↗
2021-06-15Bregua CorpPurchase (P)Common Stock58,823USD 17.00USD 999,991SEC filing ↗
2021-06-15Avalon BioVentures SPV I, L.P.; Avalon Ventures XI, L.P.Purchase (P)Common Stock629,411USD 17.00USD 10,699,987SEC filing ↗

Form 4 evidence

32 transaction lines in the latest 365-day window; 240 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-31Campbell David AlanGift (G)Common Stock123,840USD 0.00USD 0SEC filing ↗
2026-07-08Campbell David AlanOption exercise / conversion (M)Common Stock7,000USD 4.21USD 29,470SEC filing ↗
2026-06-11Simson JakeAward / grant (A)Common Stock5,500USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-31Campbell David AlanGift (G)Common Stock123,840USD 0.00USD 0SEC filing ↗
2026-07-08Campbell David AlanOption exercise / conversion (M)Common Stock7,000USD 4.21USD 29,470SEC filing ↗
2026-06-11Simson JakeAward / grant (A)Common Stock5,500USD 0.00USD 0SEC filing ↗
2026-06-11Kung WinstonAward / grant (A)Common Stock5,500USD 0.00USD 0SEC filing ↗
2026-06-11Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Award / grant (A)Common Stock5,500USD 0.00USD 0SEC filing ↗
2026-06-11Hernday NatashaAward / grant (A)Common Stock5,500USD 0.00USD 0SEC filing ↗
2026-06-11DOBMEIER ERICAward / grant (A)Common Stock5,500USD 0.00USD 0SEC filing ↗
2026-06-11CAPPS VICKIE LAward / grant (A)Common Stock5,500USD 0.00USD 0SEC filing ↗
2026-06-11Barrett Ronald WAward / grant (A)Common Stock5,500USD 0.00USD 0SEC filing ↗
2026-06-02Doyle Janeen NoelSale (S)Common Stock4,059USD 14.03USD 56,948SEC filing ↗
2026-05-11Dobek MariaSale (S)Common Stock2,038USD 14.17USD 28,878SEC filing ↗
2026-02-02Go WilliamAward / grant (A)Common Stock44,000USD 0.00USD 0SEC filing ↗
2026-01-02Winter Charles M.Sale (S)Common Stock2,401USD 13.73USD 32,966SEC filing ↗
2026-01-02Winter Charles M.Award / grant (A)Common Stock28,600USD 0.00USD 0SEC filing ↗
2026-01-02Meyer Andrew HollmanSale (S)Common Stock1,879USD 13.73USD 25,799SEC filing ↗
2026-01-02McIver ZachariahSale (S)Common Stock2,714USD 13.73USD 37,263SEC filing ↗
2026-01-02McIver ZachariahAward / grant (A)Common Stock29,000USD 0.00USD 0SEC filing ↗
2026-01-02Doyle Janeen NoelAward / grant (A)Common Stock36,000USD 0.00USD 0SEC filing ↗
2026-01-02Dobek MariaSale (S)Common Stock1,462USD 13.73USD 20,073SEC filing ↗
2026-01-02Dobek MariaAward / grant (A)Common Stock18,935USD 0.00USD 0SEC filing ↗
2026-01-02DiRaimondo ThomasSale (S)Common Stock2,505USD 13.73USD 34,394SEC filing ↗
2026-01-02DiRaimondo ThomasAward / grant (A)Common Stock31,400USD 0.00USD 0SEC filing ↗
2026-01-02Campbell David AlanSale (S)Common Stock8,072USD 13.73USD 110,829SEC filing ↗
2026-01-02Campbell David AlanAward / grant (A)Common Stock96,600USD 0.00USD 0SEC filing ↗
2025-12-01Meyer Andrew HollmanSale (S)Common Stock3,333USD 32.98USD 109,913SEC filing ↗
2025-12-01Meyer Andrew HollmanOption exercise / conversion (M)Common Stock3,333USD 10.59USD 35,296SEC filing ↗
2025-11-14Meyer Andrew HollmanSale (S)Common Stock3,333USD 30.00USD 99,990SEC filing ↗
2025-11-14Meyer Andrew HollmanOption exercise / conversion (M)Common Stock3,333USD 10.59USD 35,296SEC filing ↗
2025-10-28Meyer Andrew HollmanSale (S)Common Stock16,665USD 30.06USD 500,950SEC filing ↗
2025-10-28Meyer Andrew HollmanOption exercise / conversion (M)Common Stock16,665USD 6.76USD 112,689SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerJANX
CIK0001817713
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history240 transaction lines from 2021-06-15 to 2026-07-31
19 P purchase lines · 103 S sale lines · 118 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.